To evaluate the safety of tranexamic acid (TXA) in shoulder arthroplasty across various high-risk patient profiles.
Approach:
Study Design: Retrospective cohort study using the TriNetX Research Network database to analyze outcomes of adult patients undergoing primary total shoulder arthroplasty.
Patient Selection: Identified patients with a history of thromboembolic disease, chronic kidney disease, seizure disorder, atrial fibrillation, or visual disturbances.
Propensity Score Matching: 1:1 propensity score matching was performed to balance demographic and clinical factors between TXA and non-TXA groups.
Outcomes Assessment: Primary outcomes included 90-day postoperative complications such as transfusion, DVT, PE, myocardial infarction, seizures, and infections.
Key Findings:
TXA utilization in shoulder arthroplasty increased significantly from 2012 to 2025.
The study focused on high-risk patients who may experience complications.
Interpretation:
The study evaluates the safety of TXA in high-risk populations.
Limitations:
The study is retrospective and relies on existing database records, which may limit data accuracy.
Outcomes may not be generalizable to all patient populations due to the specific high-risk criteria used.
Conclusion:
The study seeks to determine whether TXA can be safely administered to high-risk patients undergoing shoulder arthroplasty.
